White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Texas Republicans Turn Against AI Data Centers as Election Backlash Grows 
Guatemala Receives 2,300 Mexicans Deported From US 
Trump Targets 1,000 U.S. Space Launches Annually by 2030 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Ingenia Rejects A$1.9 Billion Warburg Pincus Takeover Bid 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Trump Orders Reduction in U.S.-South Korea Military Drills, Citing Kim Jong Un Ties 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
FAA to Pause Reagan National Airport Flights for Freedom 250 IndyCar Race 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Add as a preferred source on Google
Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, branded as Nereus, marking the first new FDA-approved treatment for motion-induced vomiting in more than 40 years. The company announced that it plans to launch the drug in the United States in the coming months, a move that could significantly change the treatment landscape for motion sickness.
Motion-induced vomiting, often referred to as motion sickness, occurs when the brain receives conflicting signals from the eyes, inner ear, and body sensors. This condition commonly affects people during travel activities such as boating, driving, or flying and has long relied on older treatment options with limited innovation.
The FDA’s approval of Nereus was supported by two late-stage clinical trials involving a total of 681 patients. Results from these studies showed that tradipitant significantly reduced episodes of vomiting compared to placebo. The drug works by blocking a specific brain receptor associated with nausea and vomiting, offering a targeted and modern approach to treatment.
According to H.C. Wainwright analyst Raghuram Selvaraju, peak annual sales of tradipitant for motion sickness alone could exceed $100 million in the U.S., highlighting its strong commercial potential. Currently available motion sickness treatments include Viatris’ scopolamine patch Transderm Scop, WellSpring Pharmaceutical’s Bonine, and Prestige Consumer Healthcare’s Dramamine, many of which have been on the market for decades.
Tradipitant’s regulatory journey faced challenges in the past. In December 2018, the FDA placed a partial clinical hold on the drug, requesting additional long-term toxicity studies in dogs after classifying motion sickness as a chronic condition. However, the agency reversed its stance, reclassifying motion sickness as an acute condition and lifting the clinical hold on December 4, eliminating the need for further studies.
Vanda licensed tradipitant from Eli Lilly in 2012 and continues to study the drug for multiple indications, including gastroparesis and nausea linked to certain diabetes medications. The company has not yet disclosed pricing details for Nereus.
